^
    3ms
    Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=222, Recruiting, Revolution Medicines, Inc. | N=117 --> 222
    Enrollment change • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C
    |
    RMC-6291
    4ms
    Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=352, Recruiting, Revolution Medicines, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • RMC-6236 • RMC-6291
    5ms
    Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Revolution Medicines, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    RMC-6236 • RMC-6291
    5ms
    Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=352, Not yet recruiting, Revolution Medicines, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • RMC-6236 • RMC-6291
    6ms
    Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=210, Not yet recruiting, Revolution Medicines, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    RMC-6236 • RMC-6291
    over1year
    Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=117, Recruiting, Revolution Medicines, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C
    |
    RMC-6291
    almost2years
    Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=117, Not yet recruiting, Revolution Medicines, Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C
    |
    RMC-6291
    2years
    RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers (AACR 2022)
    In a mouse clinical trial consisting of multiple patient- and cell line-derived xenograft models of KRASG12C NSCLC, RMC-6291 outperformed adagrasib, a KRASG12C(OFF) inhibitor, by increasing the number of responses, the depth of tumor regressions, and the durability of responses.Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely by preventing reactivation of wild-type RAS proteins that cooperate with KRASG12C to fuel cancer growth. RMC-6291 also combined well with immune checkpoint inhibitors, sensitizing KRASG12C-bearing cancer models to anti-tumor immunity.RMC-6291 is a next-generation, mutant-selective inhibitor of KRASG12C(ON) that overcomes limitations of first-generation KRASG12C(OFF) inhibitors in preclinical models by directly targeting the active form of this important oncogenic driver.
    Preclinical • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • RAS wild-type
    |
    Krazati (adagrasib) • RMC-6291